Dat	e: <u>JAN. !</u>	5 th , 2023			
You	r Name:	Mariacarme	la Santarpia	M	anuscript
Title	e:	Targeted th	nerapies for KRAS-muta	ant non-small cell lung cancer: from preclinic	cal studies
to c	linical dev	relopment - a	narrative review.		
Maı	nuscript nur	mber (if known)):		
rela part to t	ted to the c ties whose i ransparency	ontent of your nterests may be and does not	manuscript. "Related" mea e affected by the content o	relationships/activities/interests listed below tha ans any relation with for-profit or not-for-profit th of the manuscript. Disclosure represents a commit If you are in doubt about whether to list a so.	ird
	following q	• • •	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	<u>t</u>
to ti med In it	he epidemio dication, eve em #1 belo	ology of hyperto en if that medic w, report all su	ension, you should declare cation is not mentioned in to the port for the work reporte	defined broadly. For example, if your manuscript pall relationships with manufacturers of antihypert the manuscript. d in this manuscript without time limit. For all oth	tensive
the	time frame	for disclosure i	s the past 36 months.		
			Name all entities with	Specifications/Comments	
			whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your institution)	
			needed) Time frame: Since the initial	mlanning of the work	
			Time frame. Since the initial	planning of the work	
		or the present	XNone		
	manuscript (e.g., runding, study materials,			
	medical writi	•			
	processing ch				
	No time limi	t for this item.			
			Time frame: past	36 months	
	Grants or cor	ntracts from	XNone		
	any entity (if	not indicated			

in item #1 above).

Royalties or licenses

_X__None

Support for attending meetings and/or travel			
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fluctary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:	4	Consulting fees	XNone
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fluctary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:			
speakers bureaus, manuscript writing or educational events 6	5		XNone
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Paceipt of equipment, materials, drugs, medical writing, gifts or other services Please summarize the above conflict of interest in the following box: Please summarize the above conflict of interest in the following box:		speakers bureaus,	
testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:		educational events	
7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:	6		XNone
8 Patents planned, issued or pending		,	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:	7		XNone
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Type of the power of th		g ,	
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Type of the power of th			
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:	8		XNone
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:		pending	
Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 2 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:	9	Participation on a Data	XNone
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options XNone			
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock optionsX_None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:		-	V 1
committee or advocacy group, paid or unpaid 11 Stock or stock options X_None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:	10		XNone
group, paid or unpaid 11 Stock or stock options XNone 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:			
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests Please summarize the above conflict of interest in the following box:			
materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests Please summarize the above conflict of interest in the following box:	11	Stock or stock options	XNone
materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests Please summarize the above conflict of interest in the following box:			
materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests Please summarize the above conflict of interest in the following box:	12	Receipt of equipment	X None
Services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:			
financial interests Please summarize the above conflict of interest in the following box:			
Please summarize the above conflict of interest in the following box:	13	Other financial or non-	XNone
_		financial interests	
_			
_			
None.	Ple	ease summarize the above c	onflict of interest in the following box:
		None.	

	e: <u>JAN.</u>			_	
		GIULIANA CI			uscript
			•	tant non-small cell lung cancer: from preclinical	studies
to (clinical dev	elopment - a i	narrative review.		
Ма	nuscript nui	mber (if known)	:		
rela par to t rela	ited to the o ties whose i ransparence itionship/ac	content of your interests may be and does not intivity/interest,	manuscript. "Related" me e affected by the content necessarily indicate a bias it is preferable that you d	Il relationships/activities/interests listed below that a eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitme . If you are in doubt about whether to list a o so.	
ma	nuscript onl	<u>γ</u> .			
to t med	he epidemidication, evoletem #1 belo	ology of hyperto en if that medic w, report all su	ension, you should declard ation is not mentioned in	e defined broadly. For example, if your manuscript per e all relationships with manufacturers of antihyperten the manuscript. ed in this manuscript without time limit. For all other Specifications/Comments (e.g., if payments were made to you or to your institution)	sive
			none (add rows as	institution	
			needed)		
			Time frame: Since the initia	al planning of the work	
	manuscript (provision of medical writ processing c	•	XNone		
					1
F			Time frame: pas	t 36 months	
	Grants or co any entity (if in item #1 ak	not indicated	XNone		

Royalties or licenses

_X__None

Support for attending meetings and/or travel			
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fluctary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:	4	Consulting fees	XNone
lectures, presentations, speakers bureaus, manuscript writing or educational events 6 Payment for expert testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fluctary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:			
speakers bureaus, manuscript writing or educational events 6	5		XNone
educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Paceipt of equipment, materials, drugs, medical writing, gifts or other services Please summarize the above conflict of interest in the following box: Please summarize the above conflict of interest in the following box:		speakers bureaus,	
testimony 7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:		educational events	
7 Support for attending meetings and/or travel 8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:	6		XNone
8 Patents planned, issued or pending		,	
8 Patents planned, issued or pending 9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:	7		XNone
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Type of the power of th		g ,	
pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Type of the power of th			
9 Participation on a Data Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:	8		XNone
Safety Monitoring Board or Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:		pending	
Advisory Board 10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options 2 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:	9	Participation on a Data	XNone
10 Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock options XNone			
in other board, society, committee or advocacy group, paid or unpaid 11 Stock or stock optionsX_None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:		-	V 1
committee or advocacy group, paid or unpaid 11 Stock or stock options X_None 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:	10		XNone
group, paid or unpaid 11 Stock or stock options XNone 12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:			
12 Receipt of equipment, materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests Please summarize the above conflict of interest in the following box:			
materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests Please summarize the above conflict of interest in the following box:	11	Stock or stock options	XNone
materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests Please summarize the above conflict of interest in the following box:			
materials, drugs, medical writing, gifts or other services 13 Other financial or non- financial interests Please summarize the above conflict of interest in the following box:	12	Receipt of equipment	X None
Services 13 Other financial or non-financial interests Please summarize the above conflict of interest in the following box:			
financial interests Please summarize the above conflict of interest in the following box:			
Please summarize the above conflict of interest in the following box:	13	Other financial or non-	XNone
_		financial interests	
_			
_			
None.	Ple	ease summarize the above c	onflict of interest in the following box:
		None.	

Date: JAN.	. 5 th , 2023	
Your Name:	CALOGERA CLAUDIA SPAGNOLO	Manuscript Title:
	herapies for KRAS-mutant non-small cell lung cancer t - a narrative review.	: from preclinical studies to clinical
Manuscript nu	umber (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None
5	Payment or honoraria for	None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
6	educational events Payment for expert	None
O	testimony	None
	testimony	
7	Support for attending	None
	meetings and/or travel	
	_	
8	Patents planned, issued or	None
	pending	
9	Participation on a Data	None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11		Neve
11	Stock or stock options	None
12	Receipt of equipment,	None
12	materials, drugs, medical	None
	writing, gifts or other	
	services	
13	Other financial or non-	None
	financial interests	
Ple	ease summarize the above c	onflict of interest in the following box:
_		
	None.	

Date: <u>JAN. 5th, 20</u>	Date:JAN. 5 th , 2023			
Your Name: And	ea Squeri			
Manuscript Title:Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclin studies to clinical development - a narrative review.				
Manuscript number (known):			
related to the conten parties whose interes to transparency and o	parency, we ask you to disclose all relationships/activities/interests listed below that are of your manuscript. "Related" means any relation with for-profit or not-for-profit third s may be affected by the content of the manuscript. Disclosure represents a commitment pes not necessarily indicate a bias. If you are in doubt about whether to list a nterest, it is preferable that you do so.			

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None
5	Payment or honoraria for	None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
6	educational events Payment for expert	None
O	testimony	None
	testimony	
7	Support for attending	None
	meetings and/or travel	
	_	
8	Patents planned, issued or	None
	pending	
9	Participation on a Data	None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11		Neve
11	Stock or stock options	None
12	Receipt of equipment,	None
12	materials, drugs, medical	None
	writing, gifts or other	
	services	
13	Other financial or non-	None
	financial interests	
Ple	ease summarize the above c	onflict of interest in the following box:
_		
	None.	

Dat	e:JAN. 5 th , 2023			
	ır Name: <u>MARIA ILENI</u>	A PASSALACQUA		
Ma	nuscript Title:Tar	geted therapies for KR.	AS-mutant non-small cell lung cancer: from preces.	clinical
Ма	nuscript number (if known)):		
rela par to t	ated to the content of your ties whose interests may be cransparency and does not	manuscript. "Related" me e affected by the content necessarily indicate a bias	eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitmer . If you are in doubt about whether to list a	
Manuscript number (if known):				
to t me In i	the epidemiology of hypertodication, even if that medicatem #1 below, report all su	ension, you should declare cation is not mentioned in pport for the work reporte	e all relationships with manufacturers of antihypertensithe manuscript.	sive
		whom you have this	(e.g., if payments were made to you or to your	
		none (add rows as needed)		
		Time frame: Since the initia	al planning of the work	
-	manuscript (e.g., funding, provision of study materials, medical writing, article	None		

Time frame: past 36 months

None

None

Grants or contracts from

in item #1 above).

Royalties or licenses

any entity (if not indicated

4	Consulting fees	None
5	Payment or honoraria for	None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
6	educational events Payment for expert	None
O	testimony	None
	testimony	
7	Support for attending	None
	meetings and/or travel	
	_	
8	Patents planned, issued or	None
	pending	
9	Participation on a Data	None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11		Neve
11	Stock or stock options	None
12	Receipt of equipment,	None
12	materials, drugs, medical	None
	writing, gifts or other	
	services	
13	Other financial or non-	None
	financial interests	
Ple	ease summarize the above c	onflict of interest in the following box:
_		
	None.	

Da	te: JAN. 5 th , 2023			
	ur Name: Andrés Aguil	lar		
			S-mutant non-small cell lung cancer: from precli	inical
	idies to clinical developm			
	•			
Ma	nuscript number (if known)):		
ا ما	the interest of transport	aala ta diaalaaa all	unlationahina/astivitias/intovatalistad halaw that an	
	-	·	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third	
	-	-	if the manuscript. Disclosure represents a commitment	
-	•		If you are in doubt about whether to list a	
	ationship/activity/interest,	•	•	
		it is preferable that you do		
The	e following questions apply	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
	nuscript only.	'	· · · · · · · · · · · · · · · · · · ·	
The	e author's relationships/act	ivities/interests should be	defined broadly. For example, if your manuscript perta	ins
to	the epidemiology of hypert	ension, you should declare	all relationships with manufacturers of antihypertensiv	⁄e
me	dication, even if that medic	cation is not mentioned in t	he manuscript.	
			d in this manuscript without time limit. For all other ite	ems,
the	time frame for disclosure i	s the past 36 months.		
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as	,	
		needed)		
		Time frame: Since the initial	planning of the work	
L	All support for the present	None		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.)			
	No time limit for this item.			

Time frame: past 36 months

None

None

Grants or contracts from

in item #1 above).

Royalties or licenses

any entity (if not indicated

4	Consulting fees	None
5	Payment or honoraria for	None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
6	educational events Payment for expert	None
O	testimony	None
	testimony	
7	Support for attending	None
	meetings and/or travel	
	_	
8	Patents planned, issued or	None
	pending	
9	Participation on a Data	None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11		Neve
11	Stock or stock options	None
12	Receipt of equipment,	None
12	materials, drugs, medical	None
	writing, gifts or other	
	services	
13	Other financial or non-	None
	financial interests	
Ple	ease summarize the above c	onflict of interest in the following box:
_		
	None.	

Date:JAN. 5 th , 2023	
Your Name: MARIA GONZALEZ CAO	
Manuscript Title:Targeted therapies for KRAS-mutant non-small cell studies to clinical development - a narrative review.	lung cancer: from preclinical
Manuscript number (if known):	
In the interest of transparency, we ask you to disclose all relationships/activities/int	

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None
5	Payment or honoraria for	None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
6	educational events Payment for expert	None
O	testimony	None
	testimony	
7	Support for attending	None
	meetings and/or travel	
	_	
8	Patents planned, issued or	None
	pending	
9	Participation on a Data	None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11		Neve
11	Stock or stock options	None
12	Receipt of equipment,	None
12	materials, drugs, medical	None
	writing, gifts or other	
	services	
13	Other financial or non-	None
	financial interests	
Ple	ease summarize the above c	onflict of interest in the following box:
_		
	None.	

Dat	te: JAN. 5 th , 2023			
	ır Name: ELISA GIOVA	NNETTI		
			S-mutant non-small cell lung cancer: from precli	inical
stu	dies to clinical developm	ient - a narrative review	•	
Ma	nuscript number (if known)):		
rela par to t	ated to the content of your ties whose interests may be	manuscript. "Related" mea e affected by the content o necessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so.	
	e following questions apply nuscript only.	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>	
to t	•	ension, you should declare	defined broadly. For example, if your manuscript perta all relationships with manufacturers of antihypertensionships. The manuscript.	
	tem #1 below, report all su time frame for disclosure i	•	d in this manuscript without time limit. For all other ite	ems,
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as needed)		
		Time frame: Since the initial	planning of the work	
	All support for the present	None		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article			
	processing charges, etc.) No time limit for this item.			
	No time minit for this item.			

Time frame: past 36 months

None

None

Grants or contracts from

in item #1 above).

Royalties or licenses

any entity (if not indicated

4	Consulting fees	None
5	Payment or honoraria for	None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
6	educational events Payment for expert	None
O	testimony	None
	testimony	
7	Support for attending	None
	meetings and/or travel	
	_	
8	Patents planned, issued or	None
	pending	
9	Participation on a Data	None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11		Neve
11	Stock or stock options	None
12	Receipt of equipment,	None
12	materials, drugs, medical	None
	writing, gifts or other	
	services	
13	Other financial or non-	None
	financial interests	
Ple	ease summarize the above c	onflict of interest in the following box:
_		
	None.	

Date: <u>JAN. 5th, 20</u>	23
Your Name: NIC	<u>OLA SILVESTRIS</u>
Manuscript Title:	Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinica
studies to clinical o	evelopment - a narrative review.
Manuscript number (if known):
related to the conter parties whose interes	sparency, we ask you to disclose all relationships/activities/interests listed below that are t of your manuscript. "Related" means any relation with for-profit or not-for-profit third ts may be affected by the content of the manuscript. Disclosure represents a commitment loes not necessarily indicate a bias. If you are in doubt about whether to list a

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None
5	Payment or honoraria for	None
	lectures, presentations,	
	speakers bureaus,	
	manuscript writing or	
6	educational events Payment for expert	None
O	testimony	None
	testimony	
7	Support for attending	None
	meetings and/or travel	
	_	
8	Patents planned, issued or	None
	pending	
9	Participation on a Data	None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy group, paid or unpaid	
11		Neve
11	Stock or stock options	None
12	Receipt of equipment,	None
12	materials, drugs, medical	None
	writing, gifts or other	
	services	
13	Other financial or non-	None
	financial interests	
Ple	ease summarize the above c	onflict of interest in the following box:
_		
	None.	

Date:	JAN. 5 th , 20	023					
Your Nan	ne: <u>R</u> A	FAEL ROSELL					
	-		ted therapies for nt - a narrative	utant non-s	small cell lui	ng cancer: fr	om preclinical
Manuscri	ipt number	(if known): _					_
		•	ve ask you to disc anuscript. "Relate	• •	-		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None		
1	Payment or honoraria for lectures, presentations, speakers bureaus,	None		
	manuscript writing or			
6	educational events Payment for expert	None		
O	testimony	None		
	testimony			
7	Support for attending	None		
	meetings and/or travel			
	_			
8	Patents planned, issued or	None		
	pending			
9	Participation on a Data	None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	None		
	in other board, society,			
	committee or advocacy group, paid or unpaid			
11		Neve		
11	Stock or stock options	None		
12	Receipt of equipment,	None		
12	materials, drugs, medical writing, gifts or other	None		
	services			
13	Other financial or non-	None		
	financial interests			
services 13 Other financial or nonNone				
	None.			